Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3571104rdf:typepubmed:Citationlld:pubmed
pubmed-article:3571104lifeskim:mentionsumls-concept:C0007226lld:lifeskim
pubmed-article:3571104lifeskim:mentionsumls-concept:C1280551lld:lifeskim
pubmed-article:3571104lifeskim:mentionsumls-concept:C0018787lld:lifeskim
pubmed-article:3571104lifeskim:mentionsumls-concept:C0002697lld:lifeskim
pubmed-article:3571104lifeskim:mentionsumls-concept:C0128513lld:lifeskim
pubmed-article:3571104lifeskim:mentionsumls-concept:C0205409lld:lifeskim
pubmed-article:3571104lifeskim:mentionsumls-concept:C1579762lld:lifeskim
pubmed-article:3571104lifeskim:mentionsumls-concept:C1979963lld:lifeskim
pubmed-article:3571104lifeskim:mentionsumls-concept:C0009491lld:lifeskim
pubmed-article:3571104lifeskim:mentionsumls-concept:C1521827lld:lifeskim
pubmed-article:3571104lifeskim:mentionsumls-concept:C2003903lld:lifeskim
pubmed-article:3571104lifeskim:mentionsumls-concept:C1524063lld:lifeskim
pubmed-article:3571104pubmed:issue4lld:pubmed
pubmed-article:3571104pubmed:dateCreated1987-6-8lld:pubmed
pubmed-article:3571104pubmed:abstractTextThe cardiac and coronary vasodilator effects of milrinone and amrinone were compared in isolated, blood-perfused papillary muscle and sinoatrial (SA) node and atrioventricular (AV) node preparations of dogs. Milrinone (0.3-100 nmol) and amrinone (0.01-3 mumol) were administered intra-arterially. Both drugs increased the force of contraction of paced and unpaced papillary muscles and the rate of automaticity of the latter; they increased sinus rate and accelerated AV nodal conduction. However, both drugs were not homogeneously effective on cardiac variables but affected them in the following order: The force of contraction of the ventricular muscle greater than SA nodal automaticity divided by AV nodal conduction greater than ventricular automaticity. In producing these cardiac effects, milrinone was 30-60 times more potent than amrinone. Both drugs increased (coronary) blood flow in all preparations. In this respect milrinone was about ten times more potent than amrinone. As a result, milrinone can be characterized as having almost equal cardiotonic and coronary vasodilatory effects, whereas amrinone is more coronary vasodilatory than cardiotonic. These differences in cardiovascular profile may contribute to their differential salutary mechanisms in the treatment of heart failure. Both drugs induced neither AV nodal tachycardia nor ventricular arrhythmia.lld:pubmed
pubmed-article:3571104pubmed:languageenglld:pubmed
pubmed-article:3571104pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3571104pubmed:citationSubsetIMlld:pubmed
pubmed-article:3571104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3571104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3571104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3571104pubmed:statusMEDLINElld:pubmed
pubmed-article:3571104pubmed:issn0910-8327lld:pubmed
pubmed-article:3571104pubmed:authorpubmed-author:WadaYYlld:pubmed
pubmed-article:3571104pubmed:authorpubmed-author:SatoYYlld:pubmed
pubmed-article:3571104pubmed:authorpubmed-author:TairaNNlld:pubmed
pubmed-article:3571104pubmed:issnTypePrintlld:pubmed
pubmed-article:3571104pubmed:volume2lld:pubmed
pubmed-article:3571104pubmed:ownerNLMlld:pubmed
pubmed-article:3571104pubmed:authorsCompleteYlld:pubmed
pubmed-article:3571104pubmed:pagination213-20lld:pubmed
pubmed-article:3571104pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3571104pubmed:meshHeadingpubmed-meshheading:3571104-...lld:pubmed
pubmed-article:3571104pubmed:meshHeadingpubmed-meshheading:3571104-...lld:pubmed
pubmed-article:3571104pubmed:meshHeadingpubmed-meshheading:3571104-...lld:pubmed
pubmed-article:3571104pubmed:meshHeadingpubmed-meshheading:3571104-...lld:pubmed
pubmed-article:3571104pubmed:meshHeadingpubmed-meshheading:3571104-...lld:pubmed
pubmed-article:3571104pubmed:meshHeadingpubmed-meshheading:3571104-...lld:pubmed
pubmed-article:3571104pubmed:meshHeadingpubmed-meshheading:3571104-...lld:pubmed
pubmed-article:3571104pubmed:meshHeadingpubmed-meshheading:3571104-...lld:pubmed
pubmed-article:3571104pubmed:meshHeadingpubmed-meshheading:3571104-...lld:pubmed
pubmed-article:3571104pubmed:meshHeadingpubmed-meshheading:3571104-...lld:pubmed
pubmed-article:3571104pubmed:meshHeadingpubmed-meshheading:3571104-...lld:pubmed
pubmed-article:3571104pubmed:meshHeadingpubmed-meshheading:3571104-...lld:pubmed
pubmed-article:3571104pubmed:meshHeadingpubmed-meshheading:3571104-...lld:pubmed
pubmed-article:3571104pubmed:year1986lld:pubmed
pubmed-article:3571104pubmed:articleTitleComparative study of cardiovascular profiles of milrinone and amrinone by use of isolated, blood-perfused dog heart preparations.lld:pubmed
pubmed-article:3571104pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3571104pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3571104pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3571104lld:pubmed